Compile Data Set for Download or QSAR
maximum 50k data
Found 933 with Last Name = 'maine' and Initial = 's'
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185336(US10011588, Example 158 | US10689373, Example 158 ...)
Affinity DataIC50:  5nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185275(US10011588, Example 91 | US10689373, Example 91 | ...)
Affinity DataIC50:  6nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185325(US10011588, Example 146 | US10689373, Example 146 ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185265(US10011588, Example 81 | US10689373, Example 81 | ...)
Affinity DataIC50:  7nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185276(US10011588, Example 92 | US10689373, Example 92 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185332(US10011588, Example 155 | US10689373, Example 155 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185287(US10011588, Example 103 | US10689373, Example 103 ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185271(US10011588, Example 87 | US10689373, Example 87 | ...)
Affinity DataIC50:  8nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185324(US10011588, Example 145 | US10689373, Example 145 ...)
Affinity DataIC50:  11nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185334(US10011588, Example 156 | US10689373, Example 156 ...)
Affinity DataIC50:  11nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185334(US10011588, Example 156 | US10689373, Example 156 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185324(US10011588, Example 145 | US10689373, Example 145 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185334(US10011588, Example 156 | US10689373, Example 156 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185324(US10011588, Example 145 | US10689373, Example 145 ...)
Affinity DataIC50:  11nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185261(US10011588, Example 77 | US10689373, Example 77 | ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US10011588, Example 142 | US10689373, Example 142 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185313(US10011588, Example 132 | US10689373, Example 132 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US10011588, Example 142 | US10689373, Example 142 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185313(US10011588, Example 132 | US10689373, Example 132 ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185321(US10011588, Example 142 | US10689373, Example 142 ...)
Affinity DataIC50:  12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185261(US10011588, Example 77 | US10689373, Example 77 | ...)
Affinity DataIC50:  12nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185313(US10011588, Example 132 | US10689373, Example 132 ...)
Affinity DataIC50:  12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185261(US10011588, Example 77 | US10689373, Example 77 | ...)
Affinity DataIC50:  12nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185323(US10011588, Example 144 | US10689373, Example 144 ...)
Affinity DataIC50:  13nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185323(US10011588, Example 144 | US10689373, Example 144 ...)
Affinity DataIC50:  13nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185323(US10011588, Example 144 | US10689373, Example 144 ...)
Affinity DataIC50:  13nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185306(US10011588, Example 125 | US10689373, Example 125 ...)
Affinity DataIC50:  14nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185306(US10011588, Example 125 | US10689373, Example 125 ...)
Affinity DataIC50:  14nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185306(US10011588, Example 125 | US10689373, Example 125 ...)
Affinity DataIC50:  14nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185304(US10011588, Example 123 | US10689373, Example 123 ...)
Affinity DataIC50:  18nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185269(US10011588, Example 85 | US10689373, Example 85 | ...)
Affinity DataIC50:  18nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185304(US10011588, Example 123 | US10689373, Example 123 ...)
Affinity DataIC50:  18nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185269(US10011588, Example 85 | US10689373, Example 85 | ...)
Affinity DataIC50:  18nMT: 2°CAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca.sup.2+ sensitive fluorescent dye. The chang...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM185304(US10011588, Example 123 | US10689373, Example 123 ...)
Affinity DataIC50:  18nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 933 total ) | Next | Last >>
Jump to: